DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, has introduced the TriLEAP lower extremity anatomic plating system (TriLEAP System) to aid foot and ankle surgeons.
The system offers a range of titanium plates for reconstructive and trauma procedures, targeting bone fixation and fusion in adults and adolescents.
The TriLEAP System is tailored for a broad spectrum of forefoot and midfoot surgeries. These procedures include bunionectomies, osteotomies, fusions, and fractures. In the US alone, 16.1% of individuals experience bunions, highlighting the demand for effective surgical solutions, according to a report.
DePuy Synthes trauma, extremities, craniomaxillofacial, animal health and sports worldwide president Oray Boston stated: “With the launch of the TriLEAP System, we now have a comprehensive portfolio for first ray surgery, which addresses conditions of the big toe, first toe bone, and foot and ankle reconstruction.
"This product is key to our strategy, which is to help advance our forefoot and midfoot portfolio to get people back on their feet. It also builds on our established orthopaedics leadership and takes us further in our goal to lead in foot and ankle care.”
The TriLEAP System's unique features include contoured and conventional titanium plates with multiple screw shaft options, including rescue screws. Its harmonised, colour-coded instrumentation is designed for ergonomic use, simplifying surgical procedures.
Atlantic Orthopaedic Specialists' board-certified orthopaedic surgeon Dr Michael Campbell said: “There’s a growing need for plating systems that offer greater precision and customisation. Foot and ankle anatomy varies widely among patients, and having plates that can adapt more precisely to individual anatomy can lead to better outcomes.
"I’m excited that the TriLEAP System is now available for first-ray surgery and foot and ankle reconstruction. The complete and specific set of tools for different procedures means we have a system that truly meets the diverse demands of the operating room, helping us provide even better care for our patients.”
In November 2023, Johnson & Johnson revealed its intention to seek investigational device exemption status from the US Food and Drug Administration for its OTTAVA robotic surgical system. This submission is scheduled for the second half of 2024 and will initiate the clinical trials for the system.
